mathom/ct_dataset huggingface dataset:
Provide exclusion criteria for trial id: NCT03861975  
 History of primary lymphedema.
Any patient with a current case of cellulitis.
Participants with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Participants unable to abduct upper-extremity perpendicular to body or to stand comfortably without aid for several minutes, both of which are necessary to perform a LymphaTech Scan
Trial Id: Clinical Evaluation of OSNA Breast Cancer System to Test Sentinel Lymph Nodes From Patients With Breast Cancer Recruitment Status: Completed Trail description: The study will determine the sensitivity, specificity, negative predictive value and positive predictive value of the OSNA Breast Cancer System by comparing its performance to permanent section Hematoxylin and Eosin (H&E) and IHC staining. Inclusion Criteria: Male or Female patients, over the age of 18, diagnosed pre-surgically with T1 or T2 breast cancer and scheduled for surgery including sentinel node dissection.
Patients who have read and understand the informed consent form and are capable and willing to provide written informed consent. Exclusion Criteria: Patients diagnosed pre-surgically with large or locally advanced (T3 and T4) breast cancers.
Patients diagnosed with inflammatory breast cancer.
Patients diagnosed with ductal carcinoma in situ (DCIS) when breast conserving is to be done.
Patients who are pregnant, as confirmed by a patient/treating physician interview.
Patients with suspicious palpable axillary lymph nodes.
Patients currently being treated for or previously diagnosed with, another type of carcinoma.
Patients who have undergone prior non-oncologic breast surgery or axillary surgery.
Patients who have received pre-operative systemic therapy.
Patients who are incapable of providing written informed consent.
Patients who have been judged to be inappropriate by a medical care provider (i.e. surgeon, oncologist, pathologists, etc.).
Provide exclusion criteria for trial id: NCT01136369  
 Patients diagnosed pre-surgically with large or locally advanced (T3 and T4) breast cancers.
Patients diagnosed with inflammatory breast cancer.
Patients diagnosed with ductal carcinoma in situ (DCIS) when breast conserving is to be done.
Patients who are pregnant, as confirmed by a patient/treating physician interview.
Patients with suspicious palpable axillary lymph nodes.
Patients currently being treated for or previously diagnosed with, another type of carcinoma.
Patients who have undergone prior non-oncologic breast surgery or axillary surgery.
Patients who have received pre-operative systemic therapy.
Patients who are incapable of providing written informed consent.
Patients who have been judged to be inappropriate by a medical care provider (i.e. surgeon, oncologist, pathologists, etc.).
Trial Id: Catheter Guided Chemo-infusion in Breast Cancer Recruitment Status: Not yet recruiting Trail description: In the present prospective study, we will analyze the outcome of image-guided delivery of intra-arterially infused chemotherapeutic drugs for patients with breast cancer in III, IV stages. Inclusion Criteria: Adult female had stage III,IV breast cancer.
Female had received no prior chemotherapy, radiotherapy, or definitive surgical therapy for breast cancer.
Patient had adequate organ function. Exclusion Criteria: Patients known to have absolute contraindications for contrast.
Patient known to have systemic organ failure.
Trial Id: Reliability And Validity Study Of "The Evaluation Tool For Myofascial Adhesions In Patients After Breast Cancer" In Turkish Language Recruitment Status: Not yet recruiting Trail description: The aim of this observational study is to translate the MAP-BC Evaluation Tool into Turkish by adapting it to Turkish society and to conduct a validity and reliability study in women who have received breast cancer treatment.

The main questions it aims to answer are:

Are the same researcher's MAP-BC Evaluation Tool results similar at intervals to detect myofascial adhesions in breast cancer patients in Turkish population?
Are the different researchers' MAP-BC Evaluation Tool results similar to detect myofascial adhesions in breast cancer patients in Turkish population?
After comparing the results of Turkish version of both The Patient and Observer Scar Assessment Scale Observer Subscale and MAP-BC Evaluation Tool, is there a sufficient correlation between them? Inclusion Criteria: None Exclusion Criteria: None
Provide description for trial id: NCT05923164  
 The aim of this observational study is to translate the MAP-BC Evaluation Tool into Turkish by adapting it to Turkish society and to conduct a validity and reliability study in women who have received breast cancer treatment.

The main questions it aims to answer are:

Are the same researcher's MAP-BC Evaluation Tool results similar at intervals to detect myofascial adhesions in breast cancer patients in Turkish population?
Are the different researchers' MAP-BC Evaluation Tool results similar to detect myofascial adhesions in breast cancer patients in Turkish population?
After comparing the results of Turkish version of both The Patient and Observer Scar Assessment Scale Observer Subscale and MAP-BC Evaluation Tool, is there a sufficient correlation between them?
Trial Id: Breast Cancer Trials Education Program Recruitment Status: Completed Trail description: The purpose of this study is to test a program designed to increase African American and Hispanic American women's scientific literacy, knowledge of clinical trials, and to facilitate breast cancer clinical trial participation. Inclusion Criteria: Self-Identified as an African American or a Hispanic American female
Speak English and/or Spanish
Mentally and Physically capable of completing the consenting process Exclusion Criteria: None
Trial Id: The Characteristics, Treatment Patterns and Prognosis of Chinese Male Breast Cancer: A Real-world Study Recruitment Status: Recruiting Trail description: The goal of this observational study is to investigate the features in Chinese male breast cancer (MBC) patients. The main question it aims to answer is:

The characteristics, treatment patterns and prognosis of Chinese MBC patients. The clinicopathological characteristics, treatment information and follow-up data of participants will be extracted from a Chinese national database (Chinese Society of Clinical Oncology Breast Cancer database) and other involved Chinese centers.

Researchers will investigate the features, survival associated factors and other relevant factors of this population. Inclusion Criteria: Biological sex is male;
Microscopically diagnosed as primary breast cancer. Exclusion Criteria: Presence of skin-origin malignancy on the breast.
Provide description for trial id: NCT06220630  
 The goal of this observational study is to investigate the features in Chinese male breast cancer (MBC) patients. The main question it aims to answer is:

The characteristics, treatment patterns and prognosis of Chinese MBC patients. The clinicopathological characteristics, treatment information and follow-up data of participants will be extracted from a Chinese national database (Chinese Society of Clinical Oncology Breast Cancer database) and other involved Chinese centers.

Researchers will investigate the features, survival associated factors and other relevant factors of this population.
Trial Id: Nurse Navigation Program Based On Health Belief Model In Breast Cancer Screening (NaHeB-CaS) Recruitment Status: Completed Trail description: This study, which is designed according to the experimental model with randomized pre-test and post-test control group, will be carried out with Syrian women who apply to Empowered Migrant Health Center in İstanbul province, Sultanbeyli district, where Syria citizens are immigranted. The population of the study consisted of all Syrian women aged 40-69 under temporary protection who came to the Empowered Migrant Health Center at the time of the research. The working group will be composed of 80 Syrian women who meet the selection criteria. According to the sources, the frequency of breast cancer screening in Turkey is taken as 15%; For the study at 95% confidence level, d=0,6 was taken and n=136 sample size was taken. Considering that there may be those who left during the research period, 14 women will be taken as substitutes and the sample will be completed to a total of 150 in order to increase the power of representing the universe. A personal questionnaire prepared by the researcher in line with the literature, Health Belief Model Scale, Mammography Self-Efficacy Scale, Champion Breast Cancer Fear Scale, Breast Self Examination Checklist Form, will be administered to Syrian women under temporary protection who applied to the empowered migrant health center and agreed to participate in the study.According to the sample pool formed by the women included in the study, the participants were assigned to 2 groups as experiment and control with the "Research Randomizer" program. Each group will be determined as 75 people. A 4-week training program will be applied to the experimental group. The women in the experimental group will be given a self-breast examination control calendar after their first training. Afterwards, motivational interviews will be held once a month for the second and third months. A "Nurse-managed screening consultancy telephone support line" will be established for Syrian women within the scope of the Nurse Navigation Program. Reminder phone calls will be made 4 times a week. Personal questionnaire, Health Belief Model Scale, Mammography Self-Efficacy Scale, Champion Breast Cancer Fear Scale, Breast Self Examination Checklist Form, Post-Training Screening Behavior Follow-up Form will be administered to the experimental and control groups as a post-test. Inclusion Criteria: Being between the ages of 40-69.
Being a woman.
Not having been diagnosed with breast cancer.
Not doing BSE on a regular basis every month.
Not having had CME and mammography in the last three years.
Not to be pregnant, breastfeeding or postpartum.
No history of breast cancer.
Not having received training on breast cancer.
To agree to participate in the research.
Absence of a mental illness.
Being literate, accessible and communicative.
Not having a communication barrier
Being registered with Sultanbeyli Empowered Migrant Health Center Exclusion Criteria: Having a problem with breast cancer before.
Having BSE, CBE or Mammography at regular intervals.
Having had a mastectomy for any reason.
Provide inclusion criteria for trial id: NCT04966377  
 Being between the ages of 40-69.
Being a woman.
Not having been diagnosed with breast cancer.
Not doing BSE on a regular basis every month.
Not having had CME and mammography in the last three years.
Not to be pregnant, breastfeeding or postpartum.
No history of breast cancer.
Not having received training on breast cancer.
To agree to participate in the research.
Absence of a mental illness.
Being literate, accessible and communicative.
Not having a communication barrier
Being registered with Sultanbeyli Empowered Migrant Health Center
Provide description for trial id: NCT04966377  
 This study, which is designed according to the experimental model with randomized pre-test and post-test control group, will be carried out with Syrian women who apply to Empowered Migrant Health Center in İstanbul province, Sultanbeyli district, where Syria citizens are immigranted. The population of the study consisted of all Syrian women aged 40-69 under temporary protection who came to the Empowered Migrant Health Center at the time of the research. The working group will be composed of 80 Syrian women who meet the selection criteria. According to the sources, the frequency of breast cancer screening in Turkey is taken as 15%; For the study at 95% confidence level, d=0,6 was taken and n=136 sample size was taken. Considering that there may be those who left during the research period, 14 women will be taken as substitutes and the sample will be completed to a total of 150 in order to increase the power of representing the universe. A personal questionnaire prepared by the researcher in line with the literature, Health Belief Model Scale, Mammography Self-Efficacy Scale, Champion Breast Cancer Fear Scale, Breast Self Examination Checklist Form, will be administered to Syrian women under temporary protection who applied to the empowered migrant health center and agreed to participate in the study.According to the sample pool formed by the women included in the study, the participants were assigned to 2 groups as experiment and control with the "Research Randomizer" program. Each group will be determined as 75 people. A 4-week training program will be applied to the experimental group. The women in the experimental group will be given a self-breast examination control calendar after their first training. Afterwards, motivational interviews will be held once a month for the second and third months. A "Nurse-managed screening consultancy telephone support line" will be established for Syrian women within the scope of the Nurse Navigation Program. Reminder phone calls will be made 4 times a week. Personal questionnaire, Health Belief Model Scale, Mammography Self-Efficacy Scale, Champion Breast Cancer Fear Scale, Breast Self Examination Checklist Form, Post-Training Screening Behavior Follow-up Form will be administered to the experimental and control groups as a post-test.
Trial Id: A Pilot Study of Working Women and Breast Cancer Recruitment Status: Completed Trail description: The purpose of this research is to better understand the relationship between employment and breast cancer. Research is being conducted to understand how workplace factors influence breast cancer patients' ability to adhere to recommended cancer treatment and effectively recover from cancer. Investigators hope to use the findings from the study to help working breast cancer survivors make informed decisions about treatment and employment in collaboration with their employers and healthcare providers. Inclusion Criteria: Women age 18-65
Working at least 20 hours per week
Currently patients of the University of Kentucky Markey Cancer Center
Are able to read, write, and communicate in English
Have reliable telephone or Internet/Web access in or outside the home Exclusion Criteria: Self-employed
Unemployed
Cognitively impaired
Trial Id: A Clinical Trial of Docetaxel and Oxaliplatin in Patients With Recurrent or Metastatic Breast Cancer Recruitment Status: Unknown status Trail description: The purpose of this study is to evaluate the overall response rate, toxicity, progression free survival and quality of life of chemotherapy with docetaxel and oxaliplatin in recurrent or metastatic breast cancer. Inclusion Criteria: Women aged : 20~70 years
WHO (ECOG) performance status 0-2
Patients with measurable lesion assessed by imaging using the RECIST (Response Evaluation Criteria In Solid Tumor) guideline
patients had previously not received chemotherapy of recurrent or metastatic lesion.
Have given written informed consent and are available for prolonged follow-up Exclusion Criteria: Patients with previous chemotherapy for recurrent breast cancer
Breast cancer recurrence within 12 months after taxane treatment
Her-2/neu expression breast cancer
Patients with malignancies (other than breast cancer) within the last 5 years, except for adequately treated in situ carcinoma of the cervix or basal cell, squamous cell carcinoma of the skin.
Brain metastasis
uncontrolled infection, medically uncontrollable heart disease
other serious medical illness or prior malignancies
Pregnant or lactating women were excluded.
Provide inclusion criteria for trial id: NCT01351597  
 Women aged : 20~70 years
WHO (ECOG) performance status 0-2
Patients with measurable lesion assessed by imaging using the RECIST (Response Evaluation Criteria In Solid Tumor) guideline
patients had previously not received chemotherapy of recurrent or metastatic lesion.
Have given written informed consent and are available for prolonged follow-up
Provide exclusion criteria for trial id: NCT01351597  
 Patients with previous chemotherapy for recurrent breast cancer
Breast cancer recurrence within 12 months after taxane treatment
Her-2/neu expression breast cancer
Patients with malignancies (other than breast cancer) within the last 5 years, except for adequately treated in situ carcinoma of the cervix or basal cell, squamous cell carcinoma of the skin.
Brain metastasis
uncontrolled infection, medically uncontrollable heart disease
other serious medical illness or prior malignancies
Pregnant or lactating women were excluded.
Trial Id: [18F] F-GLN by PET/CT in Breast Cancer Recruitment Status: Recruiting Trail description: Patients with known or suspected primary or metastatic breast cancer with one lesion that is 1.5 cm in diameter or greater may be eligible for this study. Patients may participate in this study if they are at least 18 years of age. Up to 40 evaluable subjects will participate in a single imaging cohort. Patients will be stratified for analysis by breast cancer subtype with prioritization to recruit at least 10 estrogen-receptor-expressing (ER+) and 10 triple-negative breast cancers (TNBC).

This is an observational study; [18F]F-GLN PET/CT will not be used to direct treatment decisions. While patients and referring physicians will not be blinded to the [18F]F-GLN PET/CT results, treatment decisions are made by the treating physicians based upon clinical criteria.

[18F]F-GLN PET/CT imaging sessions will include an injection of [18F]F-GLN. Metabolism data will be collected. Pilot data will be collected to evaluate image quality and collect preliminary information on the uptake of [18F]F-GLN in breast cancer. Uptake measures will be compared to tumor markers of glutamine metabolism, when tissue is available. The safety of [18F]F-GLN will also be evaluated in all subjects. Inclusion Criteria: Participants will be ≥ 18 years of age
Known or suspected primary or metastatic breast cancer.
At least one lesion ≥ 1.5 cm that is seen on standard imaging (e.g. CT, MRI, mammogram, ultrasound, FDG-PET/CT). Only one type of imaging is required to show a lesion.
Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures. Exclusion Criteria: Females who are pregnant or breast feeding at the time of screening; a urine pregnancy test will be performed in women of child-bearing potential at screening.
Inability to tolerate imaging procedures in the opinion of an investigator or treating physician.
Any current medical condition, illness, or disorder, as assessed by medical record review and/or self-reported, that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study.
Provide inclusion criteria for trial id: NCT03863457  
 Participants will be ≥ 18 years of age
Known or suspected primary or metastatic breast cancer.
At least one lesion ≥ 1.5 cm that is seen on standard imaging (e.g. CT, MRI, mammogram, ultrasound, FDG-PET/CT). Only one type of imaging is required to show a lesion.
Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.
Provide exclusion criteria for trial id: NCT03863457  
 Females who are pregnant or breast feeding at the time of screening; a urine pregnancy test will be performed in women of child-bearing potential at screening.
Inability to tolerate imaging procedures in the opinion of an investigator or treating physician.
Any current medical condition, illness, or disorder, as assessed by medical record review and/or self-reported, that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study.
Provide description for trial id: NCT03863457  
 Patients with known or suspected primary or metastatic breast cancer with one lesion that is 1.5 cm in diameter or greater may be eligible for this study. Patients may participate in this study if they are at least 18 years of age. Up to 40 evaluable subjects will participate in a single imaging cohort. Patients will be stratified for analysis by breast cancer subtype with prioritization to recruit at least 10 estrogen-receptor-expressing (ER+) and 10 triple-negative breast cancers (TNBC).

This is an observational study; [18F]F-GLN PET/CT will not be used to direct treatment decisions. While patients and referring physicians will not be blinded to the [18F]F-GLN PET/CT results, treatment decisions are made by the treating physicians based upon clinical criteria.

[18F]F-GLN PET/CT imaging sessions will include an injection of [18F]F-GLN. Metabolism data will be collected. Pilot data will be collected to evaluate image quality and collect preliminary information on the uptake of [18F]F-GLN in breast cancer. Uptake measures will be compared to tumor markers of glutamine metabolism, when tissue is available. The safety of [18F]F-GLN will also be evaluated in all subjects.
Provide inclusion criteria for trial id: NCT03482557  
 Prospective Patient Recruitment

Women
Age > or equal to 30 years
Recommendation for breast biopsy has been made
Recommendation for biopsy will result from an imaging work-up originating with a screening exam (mammogram, tomosynthesis, ultrasound, or MRI) that was within 3 months of biopsy.

Reader Study Inclusion Criteria:

CESM and MRI exam performed within 3 months of one another.
CESM and breast MRI exams must be performed as part of imaging work-up based on a screening exam of any type (mammography, tomosynthesis, ultrasound, and MRI)
CESM studies will include at least four low energy and four recombined images (LCC, LMLO, RCC, RMLO).
MRI exams will include at least fluid sensitive sequence, multi-phase T1-weighted